{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epilepsy/management/routine-epilepsy-review/","result":{"pageContext":{"chapter":{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review","depth":2,"htmlHeader":"<!-- begin field 94b7c5a5-a671-4722-9a25-fdc5e6c63155 --><h2>Scenario: Routine epilepsy review</h2><!-- end field 94b7c5a5-a671-4722-9a25-fdc5e6c63155 -->","summary":"Covers the routine review in primary care of a person with epilepsy.","htmlStringContent":"<!-- begin item a5c4b29b-c471-4d49-a924-62667f70a792 --><!-- begin field 2ae9e14e-002c-4c90-8df4-acbd0087de11 --><p>From birth onwards.</p><!-- end field 2ae9e14e-002c-4c90-8df4-acbd0087de11 --><!-- end item a5c4b29b-c471-4d49-a924-62667f70a792 -->","topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","lastRevised":"Last revised in January 2021","chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"775c4c3c-0940-5b81-8b4b-8673e2675d66","slug":"routine-epilepsy-review","fullItemName":"Routine epilepsy review","depth":3,"htmlHeader":"<!-- begin field e169a71b-f402-40fb-af5e-056a2dd99433 --><h3>How should I routinely review a person with confirmed epilepsy?</h3><!-- end field e169a71b-f402-40fb-af5e-056a2dd99433 -->","summary":null,"htmlStringContent":"<!-- begin item f0fae501-0997-4d3f-a89f-58033ceb6ed5 --><!-- begin field cb3869b1-0153-4943-bf8f-67fbf599c0a7 --><p><strong>Undertake a routine review of all people with epilepsy in primary care at least once a year. </strong></p><ul><li><strong>Ensure the person and their carers are aware of who to contact </strong>if there are problems relating to their epilepsy, such as a named epilepsy specialist nurse.<ul><li>Ensure all children and young people are reviewed by an epilepsy specialist at least once a year.</li><li>Specialist review of other people with epilepsy is at the discretion of the specialist once the diagnosis is confirmed and treatment is planned. </li></ul></li><li><strong>Assess </strong><strong>seizure control </strong>by asking about seizure frequency and severity, and any changes since the person was last reviewed. <ul><li>For people who have more than one type of seizure, identify how frequently they have each seizure type. If seizures are uncontrolled, see <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/management/routine-epilepsy-review/#when-to-seek-specialist-advice\">When to seek specialist advice</a>.</li></ul></li><li><strong>Ask about how epilepsy is affecting the person's daily functioning and quality of life, and provide advice on sources of </strong><a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/management/routine-epilepsy-review/#sources-of-information-support\">information and support</a> for the person, their family and/or carers.<ul><li>Assess for any symptoms or signs of anxiety, depression, and memory or cognitive deficit, and manage appropriately. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>, <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/depression-in-children/\">Depression in children</a>. </li><li>Ask about the impact of epilepsy on work, educational, and leisure activities; any associated difficulties or risks, and how they manage them. Check there is appropriate supervision during water activities, such as swimming, bathing, or showering, to reduce the risk of accidental drowning.</li><li>If the person is driving, or wants to drive, ensure they are entitled to do so and have contacted the Driver and Vehicle Licensing Agency (DVLA) — see the DVLA document <a data-hyperlink-id=\"701a1c09-fa7c-42e6-b462-aa5500f4770e\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/783444/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf\">Assessing fitness to drive - a guide for medical professionals</a> for more information. </li></ul></li><li><strong>Ensure that any carer for a person with epilepsy:</strong><ul><li>Is aware how to recognize and <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/management/managing-an-epileptic-seizure/#managing-an-epileptic-seizure\">manage a seizure</a>, including when and how to give buccal midazolam or rectal diazepam for prolonged or recurrent seizures, if appropriate.</li></ul></li><li><strong>Ask about any <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/prescribing-information/adverse-effects-of-antiepileptic-drugs/\">adverse effects</a> and compliance with antiepileptic drug treatment. </strong>Ensure the person (or their family or carers if appropriate) understands the importance of compliance to reduce the risk of seizures and <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/background-information/complications/\">sudden unexpected death in epilepsy (SUDEP)</a>. <ul><li>Consider whether the person should be maintained on a specific manufacturer's product by prescribing by antiepileptic drug brand name, <em>or </em>using the generic drug name and manufacturer name, if appropriate, when re-authorizing repeat prescriptions. See <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/prescribing-information/prescribing-antiepileptic-drugs/\">Prescribing antiepileptic drugs</a> for more information.</li><li>Consider measuring blood levels of antiepileptic drugs if drug toxicity or non-compliance is suspected. Seek specialist advice for blood testing in children. </li></ul></li><li><strong>For people taking antiepileptic drugs whose seizures are controlled, advise about the increased risk of osteoporosis </strong>when taking long-term carbamazepine, phenytoin, primidone, phenobarbital, or sodium valproate. <ul><li>Assess the person's risk of osteoporosis, and offer lifestyle and dietary advice and calcium and vitamin D supplementation, if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li></ul></li><li><strong>For women and girls of childbearing age, </strong>ensure that they are informed about contraception options, the risks of antiepileptic drugs during pregnancy, and how to reduce these risks when planning a pregnancy. For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/management/women-of-childbearing-age/\">Scenario: Women of childbearing age</a>. </li></ul><!-- end field cb3869b1-0153-4943-bf8f-67fbf599c0a7 --><!-- end item f0fae501-0997-4d3f-a89f-58033ceb6ed5 -->","subChapters":[{"id":"6d369da5-c561-5357-8267-367b483cbafc","slug":"sources-of-information-support","fullItemName":"Sources of information and support","depth":4,"htmlHeader":"<!-- begin field 8739aca8-cd39-491f-a671-8ca1a7c42d9e --><h4>Sources of information and support</h4><!-- end field 8739aca8-cd39-491f-a671-8ca1a7c42d9e -->","summary":null,"htmlStringContent":"<!-- begin item 2746abd7-f8da-4cca-a5fe-752dde0f6fdb --><!-- begin field b8e9f66b-9425-460f-9bd5-f5779b81cf1b --><ul><li>Ensure people with epilepsy and their families and/or carers are given, and have access to sources of, appropriately tailored information to enable them to understand epilepsy and its management (where appropriate). </li><li>Sources of information and support include:<ul><li><a data-hyperlink-id=\"5d677eee-f02d-4c20-969a-a8f7014e4734\" href=\"http://www.epilepsy.org.uk/\">Epilepsy Action</a> — provides information online, in print, and through their Epilepsy Helpline (telephone 0808 800 5050) for people with epilepsy and their family and carers.</li><li><a data-hyperlink-id=\"101f9ee0-551e-48cf-9c76-a8f7014e4e00\" href=\"http://www.epilepsysociety.org.uk/\">Epilepsy Society</a> — provides awareness campaigns, information resources, and research for anyone affected by epilepsy in the UK. The helpline (telephone 01494 601400) provides confidential emotional support.</li><li><a data-hyperlink-id=\"2933b9da-447e-479b-83eb-a8f7014e4e1c\" href=\"http://www.epilepsyresearch.org.uk/\">Epilepsy Research UK</a> — supports and promotes scientific research into the causes, treatments, and prevention of epilepsy, and provides information resources and leaflets.</li></ul></li></ul><!-- end field b8e9f66b-9425-460f-9bd5-f5779b81cf1b --><!-- end item 2746abd7-f8da-4cca-a5fe-752dde0f6fdb -->","subChapters":[]},{"id":"f7d24206-99e1-55eb-8dd9-5d84fa53dd4a","slug":"basis-for-recommendation-476","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 13f0ff7d-4c8a-457b-ab95-847d431b1722 --><h4>Basis for recommendation</h4><!-- end field 13f0ff7d-4c8a-457b-ab95-847d431b1722 -->","summary":null,"htmlStringContent":"<!-- begin item 476f781e-2adc-4705-85ac-b5a9028bb5e7 --><!-- begin field 7438c6fc-0fc7-4799-95bd-9423e807034f --><p>The recommendations about what a routine epilepsy review should include are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Diagnosis and management of epilepsy in adults</em>. SIGN advises a face-to-face annual review in primary care for all people with epilepsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. </p><h5>Named contact if issues with epilepsy and specialist review</h5><ul><li>NICE recommends that the person, their family and/or carers should have an accessible point of contact with specialist services, such as an epilepsy specialist nurse. Epilepsy specialist nurses ensure access to community and multi-agency services, as well as provide information, training, and support to the person and others involved in their care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>NICE recommends that children, young people, and adults with epilepsy are reviewed at regular intervals to ensure that they are not maintained for long periods on treatment that is ineffective or poorly tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>].</li></ul><h5>Assessing seizure control</h5><ul><li>This recommendation is based on the SIGN guideline <em>Diagnosis and management of epilepsy in adults.</em> This advises that annual review in primary care should include asking about seizure control, frequency, and date of last seizure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <ul><li>People with poorly controlled epilepsy are at increased risk of status epilepticus and sudden unexpected death in epilepsy (SUDEP) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>Failure to respond to appropriate antiepileptic drugs should prompt a review of the diagnosis of epilepsy, and compliance with drug treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. </li></ul></li></ul><h5>Impact on daily functioning and providing information and support</h5><ul><li>The recommendation about providing appropriate information and support to people, their families and carers is based on expert opinion in the NICE guideline. Potential positive outcomes of information provision include reduced mortality and morbidity, improved compliance with treatment, empowerment of individuals, and enabling people to make informed decisions about their care and quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. The SIGN guideline<em> D</em><em><em>i</em>agnosis and management of epilepsy in adults</em> states that there is a need for clear, accurate, and appropriate information and advice for people with epilepsy and their carers. SIGN also recommends the provision of information to people with epilepsy to expand their knowledge and understanding of their condition and its management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].</li><li>The recommendation to assess the person for symptoms and signs of anxiety, depression, and cognitive problems is based on the SIGN guideline <em>Diagnosis and management of epilepsy in adults </em>which notes that questions on mood and anxiety should form part of an annual primary care review and advises considering screening for depression and suicidality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].<ul><li>Psychiatric comorbidities in people with epilepsy are common, but may not be diagnosed. Around a quarter of people with epilepsy experience major depression; suicide rates of three times greater than those of the general population have been reported in people with epilepsy. Anxiety disorders affect up to a fifth of people with epilepsy, impacting on quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Cognitive problems in people with epilepsy can affect learning, memory and the ability to plan, organise, and multitask. Cognitive adverse effects have been associated with some antiepileptic medications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li></ul></li><li>Information in the NICE guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>states that people with epilepsy commonly experience difficulties with education, employment, relationships, and driving, and may have comorbidities such as attentional or learning difficulties [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>], therefore CKS advises asking about the impact of epilepsy on the person's life and associated difficulties. The recommendation on water safety is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Krishnamurthy, 2016</a>].</li><li>The recommendations on advising the person about driving are based on the NICE guideline which states that people should be given information on road safety and driving, if appropriate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>], the SIGN guideline which recommends that people with epilepsy who have a driving licence and continue to have seizures should be made aware of current Driver and Vehicle Licensing Agency (DVLA) regulations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>], and the DVLA document<em> Assessing fitness to drive - a guide for medical professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">DVLA, 2019</a>]. </li></ul><h5>Carer skills in managing a seizure</h5><ul><li>The recommendations about ensuring carers are aware of how to recognize and manage a seizure are based on expert opinion and limited evidence in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>], and expert opinion in the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Diagnosis and Management of Epilepsy in Adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <ul><li>The emergency medical treatment of seizures by carers can possibly prevent the development of status epilepticus by following an individually agreed administration protocol. Generalized tonic-clonic status epilepticus is a medical emergency with significant morbidity and mortality which can often be attributed to inadequate or delayed medical treatment of seizures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. </li></ul></li></ul><h5>Assessing adverse effects and compliance with drug treatment</h5><ul><li>The recommendation to check for adverse effects and compliance with antiepileptic drugs, and advise people that the risk of sudden unexpected death in epilepsy (SUDEP) can be minimized by optimizing seizure control, is based on expert opinion in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. The SIGN guideline <em>Diagnosis and management of epilepsy in adults </em>advises including an assessment of antiepileptic drug dose, adherence, and adverse effects as part of a primary care annual review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <em> </em><ul><li>The recommendation to consider whether the person should be maintained on a specific manufacturer's product is based on drug safety information from the Medicines and Healthcare products Regulatory Agency (MHRA) <em>Antiepileptics: updated advice on switching between different manufacturers' products </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">MHRA, 2017</a>]. </li><li>The recommendation to consider measuring blood levels of antiepileptic drugs if drug toxicity or non-compliance is suspected is based on expert opinion in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>], and the SIGN guideline <em>Diagnosis and management of epilepsy in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <ul><li>NICE states that regular blood test monitoring is not routinely recommended as it does not lead to improved seizure control for people with epilepsy, and should be done only if clinically indicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>SIGN states that there is no indication for the routine monitoring of antiepileptic drug blood level concentrations, but that measurement may be useful in the assessment of drug adherence and toxicity, if drug metabolism is likely to change (for example pregnancy), for dose adjustment of phenytoin, or in the case of unexplained loss of seizure control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li></ul></li></ul></li></ul><h5>Advising about increased risk of osteoporosis</h5><ul><li>The SIGN guideline <em>Diagnosis and management of epilepsy in adults </em>recommends that an annual review in primary care for people with epilepsy should include dietary and lifestyle advice to reduce the risk of osteoporosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]<strong>.</strong> NICE also recommends vigilance for treatment-related adverse effects such as bone health issues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>].<ul><li>The recommendation to advise about the increased risk of osteoporosis with long-term carbamazepine, phenytoin, primidone, or sodium valproate is also based on a review of data from pre-clinical and epidemiological studies, and UK Yellow Card data by the MHRA published in the Drug Safety Update <em>Antiepileptics: adverse effects on bone. </em>This states that use of these drugs is associated with loss of bone mineral density that may lead to osteopenia, osteoporosis, and increased fractures in at-risk people, and advises vitamin D supplementation should be considered for such people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">MHRA, 2009</a>].</li></ul></li></ul><h5>Advice for women and girls of childbearing age</h5><ul><li>This recommendation is consistent with the SIGN guideline <em>Diagnosis and management of epilepsy in adults, </em>that recommends women of childbearing potential taking antiepileptic drugs should be advised on contraception, conception and pregnancy at their primary care review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>],<strong> </strong>and the NICE guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li></ul><!-- end field 7438c6fc-0fc7-4799-95bd-9423e807034f --><!-- end item 476f781e-2adc-4705-85ac-b5a9028bb5e7 -->","subChapters":[]}]},{"id":"db7332cb-3598-56d0-8f88-d85fdd168f2a","slug":"when-to-seek-specialist-advice","fullItemName":"When to seek specialist advice","depth":3,"htmlHeader":"<!-- begin field f80d692d-9041-4762-be32-8ea605ba3bbc --><h3>When should I seek specialist advice for a person with confirmed epilepsy?</h3><!-- end field f80d692d-9041-4762-be32-8ea605ba3bbc -->","summary":null,"htmlStringContent":"<!-- begin item aa6d82a8-6c5c-4aa9-bb8d-52fab930f741 --><!-- begin field 4f644e6e-416c-4ab8-97a0-38b2fddd1f1a --><ul><li><strong>Seek specialist advice if a person with confirmed epilepsy has:</strong><ul><li>Poor or unacceptable seizure control, or drug treatment is poorly tolerated. </li><li>Previously had a tonic-clonic seizure lasting more than 5 minutes, or more than three seizures in an hour, and they have not previously been prescribed buccal midazolam or rectal diazepam for carers to treat future episodes.</li><li>Possible cognitive impairment secondary to epilepsy and/or its drug treatment.</li><li>Been seizure-free for the last 2 years and would like to consider tapering or withdrawing from drug treatment. Ensure the person understands:<ul><li>The risks and consequences of seizure recurrence when treatment is withdrawn.</li><li>That they are not entitled to drive from the start of the period of withdrawal and for 6 months after stopping treatment, or if seizures recur. For further information on driving entitlement, see the Driver and Vehicle Licensing Agency (DVLA) document <a data-hyperlink-id=\"0278f5ca-aa47-4ef0-92f5-aa6300c78224\" href=\"https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals\">Assessing fitness to drive: a guide for medical professionals</a>.</li></ul></li><li>Plans for a pregnancy. For more information, see the <a class=\"topic-reference internal-reference\" href=\"/topics/epilepsy/management/women-of-childbearing-age/\">Scenario: Women of childbearing age with epilepsy</a>. </li></ul></li></ul><!-- end field 4f644e6e-416c-4ab8-97a0-38b2fddd1f1a --><!-- end item aa6d82a8-6c5c-4aa9-bb8d-52fab930f741 -->","subChapters":[{"id":"c4b79c41-ecfd-5c82-95f0-e0bd0b9c703e","slug":"basis-for-recommendation-6eb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5dfdb313-65e1-4829-af40-775749ff454b --><h4>Basis for recommendation</h4><!-- end field 5dfdb313-65e1-4829-af40-775749ff454b -->","summary":null,"htmlStringContent":"<!-- begin item 6ebf971d-0f92-4707-9476-7e7f5a097aea --><!-- begin field 7411cf26-414b-4b06-b730-1166dd1188ae --><h5>Specialist advice if poor seizure control or drug treatment not tolerated</h5><ul><li>The recommendation to seek specialist advice if there is poor or unacceptable seizure control or problems with drug treatment is based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care, </em>which states that if seizures are not controlled and/or there is diagnostic uncertainty or treatment failure, people should be referred for further specialist assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. The Scottish Intercollegiate Guidelines Network (SIGN) guidelines <em>Diagnosis and management of epilepsy in adults</em><em> </em>advocates shared care for people with treatment-resistant epilepsy so that they can receive tailored management of their seizures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li></ul><h5>Specialist advice if prolonged or recurrent tonic-clonic seizures</h5><ul><li>The recommendation to seek specialist advice for people having prolonged or repeated tonic-clonic seizures regarding giving buccal midazolam or rectal diazepam to carers for emergency treatment of future episodes is based on expert opinion and limited evidence in the NICE guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>In addition, expert opinion in the SIGN guideline <em>Diagnosis and management of epilepsy in adults</em><em> </em>states that emergency medical treatment of seizures by carers can possibly prevent the development of status epilepticus by following an individually agreed administration protocol. Generalized tonic-clonic status epilepticus is a medical emergency with significant morbidity and mortality which can often be attributed to inadequate or delayed medical treatment of seizures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. </li></ul><h5>Specialist advice if possible impact on cognitive function</h5><ul><li>The recommendation to consider specialist advice if there is a concern about declining cognitive function is based on expert opinion in the NICE guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>].  <ul><li>NICE recommends that if a child, young person, or adult has or complains of memory or other cognitive deficits or decline, they should be referred for a neuropsychological assessment. It is recognized that neuropsychological deficits are associated with epilepsy (for example when there is suboptimal seizure control) and antiepileptic drug treatment, and awareness and potential management of these problems may ultimately help people's work, educational, and social functioning [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>SIGN acknowledges the distress caused by memory problems and the need for access for specialist neuropsychological opinion, if appropriate. It also recommends an epilepsy care plan for older people with cognitive problems, and suggests the inclusion of cognitive rehabilitation and psychoeducation in multidisciplinary care for people with epilepsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li></ul></li></ul><h5>Specialist advice if considering withdrawal from drug treatment</h5><ul><li>The recommendation to consider referral for advice about tapering or withdrawal from antiepileptic drug treatment if the person has been seizure-free for at least two years is based on expert opinion in the NICE guideline <em>The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>], and the SIGN guideline <em>Diagnosis and management of epilepsy in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <ul><li>NICE recommends that the decision to continue or withdraw drug treatment should be taken by the person, their family and/or carers and the specialist after a full discussion of the risks and benefits of withdrawal, taking into account the person's epilepsy syndrome, prognosis, and lifestyle. Withdrawal of drug treatment must be managed by, or under the guidance of, an epilepsy specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">National Clinical Guideline Centre, 2012b</a>]. </li><li>Antiepileptic drug withdrawal is associated with an increased risk of seizure recurrence, which is influenced by a number of factors including the seizure-free duration, history of seizure type, and drug treatment used [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>The advice on driving is based on the Driver and Vehicle Licensing Agency (DVLA) document <em>Assessing fitness to drive: a guide for medical professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">DVLA, 2019</a>].  </li></ul></li></ul><h5>Specialist advice if planning a pregnancy</h5><ul><li>The SIGN guideline <em>Diagnosis and management of epilepsy in adults </em>states that women with epilepsy should have their diagnosis and treatment, if appropriate, reviewed by specialist services before conception in order to optimise seizure control, review antiepileptic drug treatment, discuss adherence and risk of sudden unexpected death in epilepsy (SUDEP), prescribe folic acid, and discuss any genetic factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li></ul><!-- end field 7411cf26-414b-4b06-b730-1166dd1188ae --><!-- end item 6ebf971d-0f92-4707-9476-7e7f5a097aea -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}